Citius Pharmaceuticals, Inc. (CTXR) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2024. Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on oncology, anti-infectives, and stem cell therapies. The company operates through wholly-owned subsidiaries Leonard-Meron Biosciences, Inc. and Citius Oncology, Inc., and a majority-owned subsidiary, NoveCite, Inc. The company has generated no operating revenue to date and relies on capital raises to fund operations.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Nine Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(10,573,336) | $(28,348,675) |
| Net Loss Per Share (Basic & Diluted) | $(0.06) | $(0.17) |
| Operating Expenses | $10,634,179 | $30,945,203 |
| Cash and Cash Equivalents (End of Period) | $17,911,192 | |
| Working Capital | ~$23.85 million | |
| Net Cash Used in Operating Activities | $(22,288,687) (9 months) | |
| Net Cash Provided by Financing Activities | $13,718,951 (9 months) |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the nine months ended June 30, 2024, increased by approximately $5.75 million compared to the prior year period. This was primarily driven by a $5.66 million increase in stock-based compensation expense, largely due to the Citius Oncology stock plan.
- Operating Expenses: Total operating expenses increased by $4.34 million year-over-year for the nine-month period. General and administrative expenses rose by $1.63 million due to pre-launch sales and market research for LYMPHIR. Research and development expenses decreased by $2.95 million, primarily due to lower costs for the Halo-Lido Phase 2b trial.
- Capital Raise: In April 2024, the company completed a registered direct offering, raising net proceeds of approximately $13.72 million.
- Other Income: The company recognized a gain of $2.39 million from the sale of New Jersey net operating losses, compared to $3.59 million in the prior year period.
Outlook, Risks, and Unusual Items
- Going Concern: The company states that its available cash resources are sufficient to fund operations only through December 2024. This raises substantial doubt about its ability to continue as a going concern without additional financing or revenue generation.
- Merger Completion: On August 12, 2024 (subsequent to the period end), the company completed the merger of its subsidiary Citius Oncology with TenX Keane Acquisition. The combined entity is now named Citius Oncology, Inc. (Nasdaq: CTOR). Citius Pharma retains approximately 92.6% ownership of the new entity.
- Regulatory Approval: On August 8, 2024, the FDA approved LYMPHIR (denileukin diftitox) for the treatment of cutaneous T-cell lymphoma. The company is preparing for commercialization.
- NASDAQ Compliance: The company received an extension from Nasdaq until September 9, 2024, to regain compliance with the $1.00 minimum bid price requirement. Failure to comply may result in delisting.
- Unusual Items: A deemed dividend of $321,559 was recorded in the quarter due to the extension of certain warrants held by executives and placement agents.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure additional capital before December 2024 to avoid liquidity issues.
- Merger Terms: Review the final terms of the Citius Oncology spin-off/merger and the extent of Citius Pharma's remaining control and financial exposure to the new entity.
- Commercialization Timeline: Assess the timeline and costs associated with launching LYMPHIR following FDA approval.
- NASDAQ Status: Monitor the stock price to ensure compliance with the $1.00 minimum bid price rule by the September 9, 2024 deadline.
- Stock-Based Compensation: Evaluate the sustainability of high stock-based compensation expenses, particularly those related to the Citius Oncology plan, and their impact on future dilution.